TRIUMPH-5 Results: Retatrutide for Sleep Apnea
For the 30 million Americans with obstructive sleep apnea, retatrutide could mean freedom from CPAP machines. TRIUMPH-5 puts this to the test.
TRIUMPH-5 studies retatrutide for one of obesity's most disruptive complications: obstructive sleep apnea (OSA). An estimated 30 million Americans suffer from OSA, and the majority of cases are directly caused or worsened by excess weight. With retatrutide producing 24.2% average body weight loss in Phase 2 trials (Jastreboff et al., NEJM 2023), the potential to resolve sleep apnea for millions of patients is enormous. This trial could establish retatrutide as a medical alternative to lifelong CPAP dependence.
Trial in Progress
TRIUMPH-5 is ongoing. Never stop or modify CPAP therapy without consulting your sleep medicine provider.
Understanding Obstructive Sleep Apnea
Obstructive sleep apnea occurs when the upper airway repeatedly collapses during sleep, causing breathing to stop for 10 seconds or more, often hundreds of times per night. Consequences include:
- Severe daytime fatigue: Fragmented sleep prevents restorative rest
- Cardiovascular risk: OSA doubles the risk of heart attack and stroke
- Cognitive impairment: Memory, concentration, and mood are significantly affected
- Quality of life: CPAP dependence, snoring, and fatigue affect relationships and daily function
Approximately 70% of OSA patients are obese. Excess weight deposits fat around the upper airway, tongue, and neck, narrowing the airway and making collapse more likely.
How Weight Loss Resolves Sleep Apnea
Weight Loss Impact on Sleep Apnea
| Weight Loss | Expected AHI Change | Clinical Significance |
|---|---|---|
| 5-10% | Modest reduction | Some improvement in symptoms |
| 10-15% | Significant reduction | May downgrade severity |
| 15-20% | Major reduction | Many patients can stop CPAP |
| 24%+ (retatrutide) | Dramatic reduction | Potential resolution of OSA |
Weight loss reduces fat deposits in the tongue, soft palate, and lateral pharyngeal walls — the structures that collapse during apneic events. A 10% weight reduction typically reduces AHI by approximately 26%. At 24%, the reduction could approach 50-70%, potentially moving many patients from severe to mild or even normal AHI ranges.
TRIUMPH-5 Trial Design
- Population: Adults with obesity and moderate-to-severe OSA (AHI 15+)
- Estimated enrollment: ~500-800 participants
- Duration: 52-72 weeks
- Primary endpoint: Change in AHI from baseline
- Key secondary endpoints: Oxygen desaturation index, patient-reported sleepiness scores, CPAP usage, weight loss
Precedent: Tirzepatide for Sleep Apnea
Tirzepatide's SURMOUNT-OSA trial demonstrated significant AHI reductions in patients with obesity and OSA. About half of participants on tirzepatide achieved AHI below the diagnostic threshold for OSA. With retatrutide producing even greater weight loss, TRIUMPH-5 results could be even more striking.
Read more about retatrutide and sleep apnea.
What This Means for CPAP Users
- CPAP freedom: For patients who struggle with CPAP compliance, retatrutide could offer a pharmaceutical path to freedom from the machine
- Better sleep quality: Weight loss improves sleep quality beyond just reducing apneic events
- Cardiovascular protection: Resolving OSA reduces the doubled cardiovascular risk
- Energy and quality of life: Restored sleep quality improves daytime energy, mood, and cognitive function
Start Improving Sleep Today
Weight loss with current GLP-1 medications can already improve sleep apnea:
- Compounded semaglutide: $99/month
- Compounded tirzepatide: $125/month
Learn more about how to get started.
Medical Disclaimer
Retatrutide is an investigational drug not yet approved by the FDA. TRIUMPH-5 is ongoing. Never stop CPAP therapy without consulting your sleep medicine provider. Sleep apnea changes should be confirmed with follow-up polysomnography. Phase 2 data from Jastreboff et al., NEJM 2023.
Start Losing Weight, Start Sleeping Better
Semaglutide from $99/mo, tirzepatide from $125/mo — available now.
Get Started TodayMore on triumph trials
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).